Literature DB >> 17447005

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

A Isakovic1, L Harhaji, D Stevanovic, Z Markovic, M Sumarac-Dumanovic, V Starcevic, D Micic, V Trajkovic.   

Abstract

The present study reports for the first time a dual antiglioma effect of the well-known antidiabetic drug metformin. In low-density cultures of the C6 rat glioma cell line, metformin blocked the cell cycle progression in G(0)/G(1) phase without inducing significant cell death. In confluent C6 cultures, on the other hand, metformin caused massive induction of caspase-dependent apoptosis associated with c-Jun N-terminal kinase (JNK) activation, mitochondrial depolarization and oxidative stress. Metformin-triggered apoptosis was completely prevented by agents that block mitochondrial permeability transition (cyclosporin A) and oxygen radical production (N-acetylcisteine), while the inhibitors of JNK activation (SP600125) or glycolysis (sodium fluoride, iodoacetate) provided partial protection. The antiglioma effect of metformin was reduced by compound C, an inhibitor of AMP-activated protein kinase (AMPK), and was mimicked by the AMPK agonist AICAR. Similar effects were observed in the human glioma cell line U251, while rat primary astrocytes were completely resistant to the antiproliferative and proapoptotic action of metformin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17447005     DOI: 10.1007/s00018-007-7080-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  83 in total

1.  Pre-stroke Metformin Treatment is Neuroprotective Involving AMPK Reduction.

Authors:  Tian Deng; Yan-Rong Zheng; Wei-Wei Hou; Yang Yuan; Zhe Shen; Xiao-Li Wu; Ying Chen; Li-San Zhang; Wei-Wei Hu; Zhong Chen; Xiang-Nan Zhang
Journal:  Neurochem Res       Date:  2016-06-27       Impact factor: 3.996

2.  Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.

Authors:  Corinna Seliger; Anne-Louise Meyer; Kathrin Renner; Verena Leidgens; Sylvia Moeckel; Birgit Jachnik; Katja Dettmer; Ulrike Tischler; Valeria Gerthofer; Lisa Rauer; Martin Uhl; Martin Proescholdt; Ulrich Bogdahn; Markus J Riemenschneider; Peter J Oefner; Marina Kreutz; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  Cell Cycle       Date:  2016-05-10       Impact factor: 4.534

3.  Metformin intake is associated with better survival in ovarian cancer: a case-control study.

Authors:  Sanjeev Kumar; Alexandra Meuter; Prabin Thapa; Carrie Langstraat; Shailendra Giri; Jeremy Chien; Ramandeep Rattan; William Cliby; Viji Shridhar
Journal:  Cancer       Date:  2012-12-03       Impact factor: 6.860

4.  Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1.

Authors:  Yong P Hwang; Hye G Jeong
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent.

Authors:  Xiaona Liu; Rishi Raj Chhipa; Ichiro Nakano; Biplab Dasgupta
Journal:  Mol Cancer Ther       Date:  2014-01-13       Impact factor: 6.261

Review 6.  Cellular and molecular mechanisms of metformin: an overview.

Authors:  Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli
Journal:  Clin Sci (Lond)       Date:  2012-03       Impact factor: 6.124

7.  Metformin induced expression of Hsp60 in human THP-1 monocyte cells.

Authors:  An-Chi Tsuei; Ryan Dennis Martinus
Journal:  Cell Stress Chaperones       Date:  2011-07-16       Impact factor: 3.667

8.  Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.

Authors:  Xuejun Yang; Deguang Sun; Yu Tian; Sunbin Ling; Liming Wang
Journal:  Tumour Biol       Date:  2014-12-11

9.  Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Authors:  Stefania Maraka; Morris D Groves; Aaron G Mammoser; Isaac Melguizo-Gavilanes; Charles A Conrad; Ivo W Tremont-Lukats; Monica E Loghin; Barbara J O'Brien; Vinay K Puduvalli; Erik P Sulman; Kenneth R Hess; Kenneth D Aldape; Mark R Gilbert; John F de Groot; W K Alfred Yung; Marta Penas-Prado
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

10.  Metformin influences progression in diabetic glioblastoma patients.

Authors:  Sebastian Adeberg; Denise Bernhardt; Semi Ben Harrabi; Tilman Bostel; Angela Mohr; Christian Koelsche; Christian Diehl; Stefan Rieken; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2015-09-02       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.